Bridgeway Capital Management LLC Sells 25,000 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Bridgeway Capital Management LLC cut its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 7.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 331,624 shares of the biotechnology company’s stock after selling 25,000 shares during the quarter. Bridgeway Capital Management LLC’s holdings in CytomX Therapeutics were worth $342,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of CTMX. Schonfeld Strategic Advisors LLC raised its holdings in shares of CytomX Therapeutics by 13.9% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 1,380,800 shares of the biotechnology company’s stock valued at $1,422,000 after purchasing an additional 169,000 shares during the period. Renaissance Technologies LLC raised its stake in CytomX Therapeutics by 32.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,346,800 shares of the biotechnology company’s stock worth $1,387,000 after buying an additional 331,800 shares during the period. JPMorgan Chase & Co. raised its stake in CytomX Therapeutics by 288,736.3% during the 4th quarter. JPMorgan Chase & Co. now owns 811,630 shares of the biotechnology company’s stock worth $836,000 after buying an additional 811,349 shares during the period. Monimus Capital Management LP bought a new position in CytomX Therapeutics in the fourth quarter worth approximately $375,000. Finally, Northern Trust Corp lifted its holdings in shares of CytomX Therapeutics by 16.0% in the 4th quarter. Northern Trust Corp now owns 150,632 shares of the biotechnology company’s stock worth $155,000 after purchasing an additional 20,746 shares in the last quarter. 67.77% of the stock is currently owned by institutional investors and hedge funds.

CytomX Therapeutics Price Performance

NASDAQ CTMX opened at $2.13 on Tuesday. The company has a fifty day moving average price of $0.69 and a 200-day moving average price of $0.86. CytomX Therapeutics, Inc. has a 1 year low of $0.40 and a 1 year high of $2.18. The firm has a market cap of $171.72 million, a price-to-earnings ratio of 12.53 and a beta of 1.11.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. The business had revenue of $50.92 million during the quarter, compared to the consensus estimate of $35.42 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. During the same period in the prior year, the firm posted $0.17 EPS. On average, research analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on CTMX shares. HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. StockNews.com began coverage on CytomX Therapeutics in a research note on Tuesday, April 15th. They set a “hold” rating for the company. Wedbush reissued an “outperform” rating and set a $6.00 price objective (up from $5.00) on shares of CytomX Therapeutics in a report on Monday. Finally, Piper Sandler initiated coverage on CytomX Therapeutics in a report on Monday, April 14th. They issued an “overweight” rating and a $2.50 target price on the stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.